Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC - European Medical Journal

Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC

Oncology
At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomised phase 3 clinical trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage 4 non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>